MEMBER'S LOGINX
| Login Failure | ||||||||
|
||||||||
| Sign Up | Forgot Password? | ||||||||
- Home
- Research It
- SUVEN LIFE SCIENCES LTD. (pharmaceuticals)
- SUVEN LIFE SCIENCES LTD. Financial Data
SUVEN LIFE Fact Sheet (SVNP)
REVEALED: How to Potentially Increase Your Monthly Income Without Working 24x7
Here is the latest financial fact sheet of SUVEN LIFE. For more details, see the SUVEN LIFE quarterly results and SUVEN LIFE share price and chart. For a sector overview, read our pharmaceuticals sector report.
SUVEN LIFESCIENCES Price History
| % ch | % | 20.0 |
| No. of shares | m | 127.28 |
| % ch week | % | 23.2 |
| % ch 1-mth | % | 30.0 |
| % ch 12-mth | % | -78.1 |
| 52 week H/L | Rs | 321.9/19.4 |
SUVEN LIFESCIENCES Financials
| No. of Mths Year Ending |
12 Mar-15 |
12 Mar-16 |
12 Mar-17 |
12 Mar-18 |
12 Mar-19 |
5-Yr Chart Click to enlarge
|
|---|
| SUVEN LIFESCIENCES EQUITY SHARE DATA | |||||||
|---|---|---|---|---|---|---|---|
| High | Rs | 323 | 339 | 229 | 251 | 338 | |
| Low | Rs | 72 | 144 | 151 | 155 | 169 | |
| Sales per share (Unadj.) | Rs | 40.9 | 39.2 | 42.7 | 49.1 | 52.1 | |
| Earnings per share (Unadj.) | Rs | 8.5 | 5.6 | 6.9 | 9.7 | 6.8 | |
| Diluted earnings per share | Rs | 8.5 | 5.6 | 6.8 | 9.7 | 6.8 | |
| Cash flow per share (Unadj.) | Rs | 9.5 | 7.0 | 8.5 | 11.4 | 8.6 | |
| Dividends per share (Unadj.) | Rs | 0.60 | 2.00 | 1.00 | 1.50 | 1.50 | |
| Adj. dividends per share | Rs | 0.60 | 2.00 | 1.00 | 1.50 | 1.50 | |
| Dividend yield (eoy) | % | 0.3 | 0.8 | 0.5 | 0.7 | 0.6 | |
| Book value per share (Unadj.) | Rs | 44.3 | 46.8 | 52.4 | 60.3 | 65.3 | |
| Adj. book value per share | Rs | 44.3 | 46.8 | 52.4 | 60.3 | 65.3 | |
| Shares outstanding (eoy) | m | 127.28 | 127.28 | 127.28 | 127.28 | 127.28 | |
| Bonus/Rights/Conversions | IS | - | - | - | - | ||
| Price / Sales ratio | x | 4.8 | 6.2 | 4.4 | 4.1 | 4.9 | |
| Avg P/E ratio | x | 23.1 | 42.8 | 27.7 | 20.9 | 37.1 | |
| P/CF ratio (eoy) | x | 20.8 | 34.4 | 22.2 | 17.8 | 29.6 | |
| Price / Book Value ratio | x | 4.5 | 5.2 | 3.6 | 3.4 | 3.9 | |
| Dividend payout | % | 7.0 | 35.4 | 14.6 | 15.4 | 22.0 | |
| Avg Mkt Cap | Rs m | 25,100 | 30,732 | 24,158 | 25,825 | 32,272 | |
| No. of employees | `000 | 0.9 | 1.0 | 1.0 | 1.1 | 1.1 | |
| Total wages/salary | Rs m | 365 | 409 | 522 | 613 | 661 | |
| Avg. sales/employee | Rs Th | 5,912.1 | 5,236.1 | 5,349.7 | 5,832.6 | 6,132.2 | |
| Avg. wages/employee | Rs Th | 414.4 | 429.1 | 513.5 | 571.5 | 611.1 | |
| Avg. net profit/employee | Rs Th | 1,234.4 | 753.0 | 858.1 | 1,153.8 | 803.5 | |
| SUVEN LIFESCIENCES INCOME DATA | |||||||
|---|---|---|---|---|---|---|---|
| Net Sales | Rs m | 5,209 | 4,995 | 5,435 | 6,253 | 6,635 | |
| Other income | Rs m | 86 | 194 | 211 | 233 | 242 | |
| Total revenues | Rs m | 5,294 | 5,189 | 5,646 | 6,485 | 6,877 | |
| Gross profit | Rs m | 1,595 | 1,016 | 1,291 | 1,982 | 1,604 | |
| Depreciation | Rs m | 118 | 175 | 214 | 213 | 221 | |
| Interest | Rs m | 47 | 59 | 57 | 46 | 38 | |
| Profit before tax | Rs m | 1,516 | 976 | 1,231 | 1,955 | 1,587 | |
| Minority Interest | Rs m | 0 | 0 | 0 | 0 | 0 | |
| Prior Period Items | Rs m | 0 | 0 | 0 | 0 | 0 | |
| Extraordinary Inc (Exp) | Rs m | 0 | 0 | 0 | 0 | 0 | |
| Tax | Rs m | 428 | 257 | 359 | 718 | 718 | |
| Profit after tax | Rs m | 1,088 | 718 | 872 | 1,237 | 869 | |
| Gross profit margin | % | 30.6 | 20.3 | 23.7 | 31.7 | 24.2 | |
| Effective tax rate | % | 28.2 | 26.4 | 29.2 | 36.7 | 45.2 | |
| Net profit margin | % | 20.9 | 14.4 | 16.0 | 19.8 | 13.1 | |
| SUVEN LIFESCIENCES BALANCE SHEET DATA | |||||||
|---|---|---|---|---|---|---|---|
| Current assets | Rs m | 4,494 | 4,277 | 4,917 | 5,696 | 6,232 | |
| Current liabilities | Rs m | 1,185 | 1,107 | 1,186 | 1,216 | 1,490 | |
| Net working cap to sales | % | 63.5 | 63.5 | 68.6 | 71.6 | 71.5 | |
| Current ratio | x | 3.8 | 3.9 | 4.1 | 4.7 | 4.2 | |
| Inventory Days | Days | 57 | 61 | 62 | 81 | 86 | |
| Debtors Days | Days | 28 | 39 | 31 | 36 | 83 | |
| Net fixed assets | Rs m | 2,790 | 3,126 | 3,154 | 3,325 | 4,043 | |
| Share capital | Rs m | 127 | 127 | 127 | 127 | 127 | |
| "Free" reserves | Rs m | 5,510 | 5,826 | 6,543 | 7,547 | 8,183 | |
| Net worth | Rs m | 5,637 | 5,953 | 6,670 | 7,674 | 8,310 | |
| Long term debt | Rs m | 594 | 416 | 259 | 22 | 18 | |
| Total assets | Rs m | 7,456 | 7,515 | 8,157 | 9,192 | 10,389 | |
| Interest coverage | x | 33.2 | 17.6 | 22.7 | 43.2 | 43.1 | |
| Debt to equity ratio | x | 0.1 | 0.1 | 0 | 0 | 0 | |
| Sales to assets ratio | x | 0.7 | 0.7 | 0.7 | 0.7 | 0.6 | |
| Return on assets | % | 15.2 | 10.3 | 11.4 | 14.0 | 8.7 | |
| Return on equity | % | 19.3 | 12.1 | 13.1 | 16.1 | 10.5 | |
| Return on capital | % | 25.1 | 16.2 | 18.6 | 26.0 | 19.5 | |
| Exports to sales | % | 88.1 | 87.5 | 0 | 0 | 0 | |
| Imports to sales | % | 11.6 | 12.2 | 0 | 0 | 0 | |
| Exports (fob) | Rs m | 4,590 | 4,371 | 0 | 0 | 0 | |
| Imports (cif) | Rs m | 602 | 611 | 0 | 0 | 0 | |
| Fx inflow | Rs m | 4,779 | 4,666 | 4,943 | 5,066 | 5,622 | |
| Fx outflow | Rs m | 855 | 942 | 1,857 | 2,001 | 1,799 | |
| Net fx | Rs m | 3,924 | 3,724 | 3,086 | 3,065 | 3,822 | |
| SUVEN LIFESCIENCES CASH FLOW | |||||||
|---|---|---|---|---|---|---|---|
| From Operations | Rs m | 1,429 | 675 | 1,092 | 699 | 356 | |
| From Investments | Rs m | -1,105 | -386 | -3,107 | -6 | -279 | |
| From Financial Activity | Rs m | 1,791 | -681 | -304 | -521 | -225 | |
| Net Cashflow | Rs m | 2,116 | -392 | -2,319 | 173 | -148 | |
Share Holding
|
Company Information
|
|||||||||||||||||||||||||||||||||||||||||
| COMP SEC: K. Hanumantha Rao | YEAR OF INC: 1989 | BSE CODE: 530239 | FV (Rs): 1 | DIV YIELD (%): 2.6 |
Read: SUVEN LIFESCIENCES 2018-19 Annual Report Analysis
More Pharmaceuticals Company Fact Sheets: CIPLA AUROBINDO PHARMA VENUS REMEDIES FDC. ASTRAZENECA PHARMA
Compare SUVEN LIFESCIENCES With: CIPLA AUROBINDO PHARMA VENUS REMEDIES FDC. ASTRAZENECA PHARMA
Compare SUVEN LIFESCIENCES With: ADCOCK INGRAM (S. Africa) MYLAN (US) ACTAVIS (US) TEVA PHARMA (Israel)
Today's Market
Sensex Ends Flat; Maruti Suzuki Rallies 7.5%(Closing)
After opening the day at record high levels, Indian share markets erased gains as the session progressed and ended on a flat note, led by a decline in IT stocks and index heavyweight HDFC Bank.
Views on news
SUVEN LIFESCIENCES Announces Quarterly Results (1QFY20); Net Profit Up 47.2% (Quarterly Result Update)
Aug 28, 2019 | Updated on Aug 28, 2019For the quarter ended June 2019, SUVEN LIFESCIENCES has posted a net profit of Rs 572 m (up 47.2% YoY). Sales on the other hand came in at Rs 2 bn (up 3.8% YoY). Read on for a complete analysis of SUVEN LIFESCIENCES's quarterly results.
SUVEN LIFESCIENCES 2018-19 Annual Report Analysis (Annual Result Update)
Jul 22, 2019 | Updated on Jul 22, 2019Here's an analysis of the annual report of SUVEN LIFESCIENCES for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of SUVEN LIFESCIENCES. Also includes updates on the valuation of SUVEN LIFESCIENCES.
SUVEN LIFESCIENCES Announces Quarterly Results (4QFY19); Net Profit Up 8.7% (Quarterly Result Update)
May 27, 2019 | Updated on May 27, 2019For the quarter ended March 2019, SUVEN LIFESCIENCES has posted a net profit of Rs 680 m (up 8.7% YoY). Sales on the other hand came in at Rs 3 bn (up 18.5% YoY). Read on for a complete analysis of SUVEN LIFESCIENCES's quarterly results.
More Views on NewsMost Popular
Not Infosys or Wipro. India's Next Wealth Creators Could Be Drone Stocks (Profit Hunter)
Nov 25, 2020India's drones directorate signals the next big defence tech multibaggers.
It's Time to Book Profits (Fast Profits Daily)
Nov 27, 2020In my first video on Equitymaster, I want to introduce you my proprietary greed and fear index. It's telling us to book some profits in the market.
How the New Margins Will Impact You (Fast Profits Daily)
Nov 25, 2020The new rules on margins will come into effect from 1st December. Are you ready?
Create Wealth for Yourself in India's Drone Revolution (Profit Hunter)
Nov 27, 2020The Chinese drone market is 14 times that of India's. Billions may flow into Indian drone companies too. Don't miss out on this wealth creating opportunity.
The Price of Dying, the Cost of Living (The Honest Truth)
Nov 20, 2020Ajit Dayal presents a cost benefit analysis of the various types of response to covid around the world.
MoreOUR TOP 5 IDEAS
- Free Report: Multibagger Stock Ideas 2021
- Are You Making One of These 15 Costly Mistakes While Investing. Learn more!
- Covid-19 Proof Multibagger Stocks - Download this FREE Report Now
- Free Report: The Secret to Increasing Your Trading Profits Daily!
- No Guessing, No Hunches, and No Missed Trends Ever! Join Us on YouTube Now.
TRACK SUVEN LIFESCIENCES
- Track your investment in SUVEN LIFESCIENCES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
- Add To MyStocks
MORE ON SUVEN LIFESCIENCES
SUVEN LIFESCIENCES - STRIDES PHARMA SCIENCE COMPARISON
COMPARE SUVEN LIFESCIENCES WITH
MARKET STATS
ABOUT EQUITYMASTER
Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.
FREE NEWSLETTERS
PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
- Basics of Value Investing
- Benjamin Graham
- How to Invest in Gold
- How to Invest in Silver
- Best Stocks to Buy Today
- Warren Buffett - The Value Investor
- The Best Small-cap Stocks to Buy
- The Best Bluechip Stocks to Buy
- Your Ultimate Guide to Penny Stock Investing
- 10 Rules for Successful Long-Term Investing
- How to Invest in the Share Market
FOLLOW
APP
Copyright © Equitymaster Agora Research Private Limited.
Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap
Equitymaster Agora Research Private Limited (Research Analyst) 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.